Bristol-Myers Squibb (NYSE:BMY) had its price target increased by Barclays from $55.00 to $58.00 in a report issued on Friday. The firm currently has an equal weight rating on the biopharmaceutical company’s stock.
A number of other research analysts have also issued reports on the stock. Credit Suisse Group reiterated a hold rating and issued a $61.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 12th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from an underweight rating to a neutral rating and set a $57.00 target price on the stock in a research note on Wednesday, August 8th. SunTrust Banks reiterated a buy rating and issued a $67.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, July 31st. JPMorgan Chase & Co. raised their target price on shares of Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an overweight rating in a research note on Monday, October 8th. Finally, Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the company a hold rating in a research note on Sunday, July 15th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $63.13.
NYSE:BMY traded up $0.01 during midday trading on Friday, reaching $57.51. The stock had a trading volume of 10,484,764 shares, compared to its average volume of 7,383,813. Bristol-Myers Squibb has a 1-year low of $49.96 and a 1-year high of $70.05. The company has a current ratio of 1.40, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $101.47 billion, a PE ratio of 19.11, a PEG ratio of 1.70 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The business had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. During the same period last year, the business posted $0.74 EPS. Bristol-Myers Squibb’s revenue was up 10.9% compared to the same quarter last year. As a group, analysts anticipate that Bristol-Myers Squibb will post 3.62 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date is Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.
A number of institutional investors have recently modified their holdings of BMY. CSat Investment Advisory L.P. bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth about $113,000. Landaas & Co. WI ADV bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth about $131,000. Mount Yale Investment Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $179,000. Selective Wealth Management bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $184,000. Finally, LFA Lugano Financial Advisors SA lifted its holdings in shares of Bristol-Myers Squibb by 85.8% during the 3rd quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 1,481 shares during the period. 72.28% of the stock is owned by hedge funds and other institutional investors.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.